Bartels, Claudia

[["dc.bibliographiccitation.journal","Frontiers in Psychiatry"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Hansen, Niels"],["dc.contributor.author","Hirschel, Sina"],["dc.contributor.author","Stöcker, Winfried"],["dc.contributor.author","Manig, Anja"],["dc.contributor.author","Falk, Hannah Sönne"],["dc.contributor.author","Ernst, Marielle"],["dc.contributor.author","Vukovich, Ruth"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Bartels, Claudia"],["dc.date.accessioned","2021-04-14T08:23:48Z"],["dc.date.available","2021-04-14T08:23:48Z"],["dc.date.issued","2020"],["dc.description.abstract","Background IgLON5 disease is an autoimmune disorder that shares neuropathological aspects with a tauopathy. Its clinical spectrum is heterogeneous, and figural memory impairment as an initial phenomenon of IgLON5 syndrome has not yet been described. The rationale of this report is to highlight symptoms related to IgLON5 disease that have not been reported to date. This case report will thereby emphasize how important it is to initiate thorough diagnostic methods including cerebrospinal fluid analysis (CSF) before starting early immunotherapy. Methods We examined a 65-year-old Caucasian male via neuropsychological tests, magnetic resonance imaging (MRI), electroencephalography (EEG), neurography and polysomnography. He also underwent two lumbar punctures from which we determined specific autoantibodies in cerebrospinal (CSF) and peripheral blood (PB). Results The patient presented initially complaining of memory loss, gradual dysphagia and sleeping dysfunction. Neuropsychological testing at first presentation and follow-up revealed subtle figural and working memory impairment. At onset and at his 6-month follow-up, we detected IgLON5 antibodies in CSF and PB. Furthermore, we identified in the CSF a blood–brain barrier disturbance at disease onset and follow-up, and markers of neuroaxonal damage such as mildly elevated phosphorylated Tau-181 protein with 86 pg/ml (normal range ≤ 61 pg/ml) at onset. Three months after his initial presentation, he was suffering from axonal neuropathy and transient ataxia in the extremities. Assuming a definitive autoimmune encephalitis-associated with anti-IgLON5 antibodies, we applied high-dose steroids monthly (1g methylprednisolone i.v. for five consecutive days) and his memory complaints, ataxia of extremities and peripheral neuropathy as well as sleeping dysfunction decreased. Conclusions Our findings broaden IgLON5 disease’s clinical spectrum to include predominant and discrete figural memory impairment together with sleeping dysfunction at disease onset. In addition, our report illustrates how important taking an elaborated diagnostic approach is to assuring an accurate diagnosis and the appropriate therapy if a patient presents with a persisting figural memory impairment and sleeping abnormalities so as to avoid overlooking IgLON5 disease and a potentially poor outcome."],["dc.identifier.doi","10.3389/fpsyt.2020.00576"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17685"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81054"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1664-0640"],["dc.relation.haserratum","/handle/2/83966"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Figural Memory Impairment in Conjunction With Neuropsychiatric Symptoms in IgLON5 Antibody-Associated Autoimmune Encephalitis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Psychiatry"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Hansen, Niels"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Stöcker, Winfried"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Fitzner, Dirk"],["dc.date.accessioned","2022-04-01T10:00:39Z"],["dc.date.available","2022-04-01T10:00:39Z"],["dc.date.issued","2022"],["dc.description.abstract","Background Glycine receptor antibody-associated neuropsychiatric disease is currently known to be dominated by the phenotypes stiff-person syndrome and progressive encephalomyelitis entailing rigidity and myoclonus. In our case series we aim to depict the less-often reported feature of cognitive impairment associated with glycine receptor antibodies. Methods We investigated five patients with cognitive impairment varying from mild cognitive impairment to dementia associated with serum glycine receptor antibodies. Mild and major neurocognitive disorders were diagnosed according to the DSM-5 (fifth edition of the Diagnostic and Statistical Manual of Mental Disorders). Neuropsychology via Consortium to Establish a Registry for Alzheimer's Disease (CERAD) testing results, psychopathology data via the Manual for the Assessment and Documentation of Psychopathology in Psychiatry (AMDP), cerebrospinal fluid analysis and magnetic resonance imaging data were retrospectively analyzed from patient files. Results We identified five patients with cognitive impairment as the main neuropsychiatric feature associated with serum glycine receptor antibodies. One patient also presented akinetic rigidity syndrome. The psychopathology comprised disorders of attention and memory, orientation, formal thought, and affect. In addition to suffering deficits in verbal memory function, figural recall, phonematic fluency, and globally deteriorated cognitive function, these patients presented seriously impaired memory recall in particular. Tau protein and phosphorylated tau protein 181 were elevated in 75% of patients. Conclusions Our results suggest that axonal neurodegeneration and especially impaired verbal memory recall in addition to deficits in verbal and figural memory characterize patients with progressive cognitive impairment associated with glycine receptor antibodies. This unresolved issue should be clarified by researchers to discover whether axonal degeneration is merely an age-related phenomenon or one related to glycine-receptor autoantibodies in old age. Cognitive impairment as a neuropsychiatric syndrome of glycine-receptor antibody disease is a potential, conceivable, but so far unproven additional feature requiring deeper large-scale investigations and consideration during differential diagnosis in memory clinics."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3389/fpsyt.2021.778684"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105481"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1664-0640"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Impaired Verbal Memory Recall in Patients With Axonal Degeneration and Serum Glycine-Receptor Autoantibodies—Case Series"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","945709"],["dc.bibliographiccitation.journal","Frontiers in Psychology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.affiliation","Böttcher, Adriana; 1German Center for Neurodegenerative Diseases, Dresden, Germany"],["dc.contributor.affiliation","Zarucha, Alexis; 1German Center for Neurodegenerative Diseases, Dresden, Germany"],["dc.contributor.affiliation","Köbe, Theresa; 1German Center for Neurodegenerative Diseases, Dresden, Germany"],["dc.contributor.affiliation","Gaubert, Malo; 1German Center for Neurodegenerative Diseases, Dresden, Germany"],["dc.contributor.affiliation","Höppner, Angela; 1German Center for Neurodegenerative Diseases, Dresden, Germany"],["dc.contributor.affiliation","Altenstein, Slawek; 3German Center for Neurodegenerative Diseases, Berlin, Germany"],["dc.contributor.affiliation","Bartels, Claudia; 5Department of Psychiatry and Psychotherapy, University Medical Center, University of Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Buerger, Katharina; 6Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany"],["dc.contributor.affiliation","Dechent, Peter; 8MR-Research in Neurology and Psychiatry, Georg-August-University Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Dobisch, Laura; 9German Center for Neurodegenerative Diseases, Magdeburg, Germany"],["dc.contributor.affiliation","Ewers, Michael; 7German Center for Neurodegenerative Diseases, Munich, Germany"],["dc.contributor.affiliation","Fliessbach, Klaus; 11German Center for Neurodegenerative Diseases, Bonn, Germany"],["dc.contributor.affiliation","Freiesleben, Silka Dawn; 4Department of Psychiatry, Charité – Universitätsmedizin Berlin, Berlin, Germany"],["dc.contributor.affiliation","Frommann, Ingo; 11German Center for Neurodegenerative Diseases, Bonn, Germany"],["dc.contributor.affiliation","Haynes, John Dylan; 13Bernstein Center for Computational Neuroscience, Charité – Universitätsmedizin, Berlin, Germany"],["dc.contributor.affiliation","Janowitz, Daniel; 6Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany"],["dc.contributor.affiliation","Kilimann, Ingo; 14German Center for Neurodegenerative Diseases, Rostock, Germany"],["dc.contributor.affiliation","Kleineidam, Luca; 11German Center for Neurodegenerative Diseases, Bonn, Germany"],["dc.contributor.affiliation","Laske, Christoph; 16German Center for Neurodegenerative Diseases, Tübingen, Germany"],["dc.contributor.affiliation","Maier, Franziska; 18Department of Psychiatry, Faculty of Medicine, University of Cologne, Cologne, Germany"],["dc.contributor.affiliation","Metzger, Coraline; 9German Center for Neurodegenerative Diseases, Magdeburg, Germany"],["dc.contributor.affiliation","Munk, Matthias H. J.; 16German Center for Neurodegenerative Diseases, Tübingen, Germany"],["dc.contributor.affiliation","Perneczky, Robert; 7German Center for Neurodegenerative Diseases, Munich, Germany"],["dc.contributor.affiliation","Peters, Oliver; 3German Center for Neurodegenerative Diseases, Berlin, Germany"],["dc.contributor.affiliation","Priller, Josef; 3German Center for Neurodegenerative Diseases, Berlin, Germany"],["dc.contributor.affiliation","Rauchmann, Boris-Stephan; 23Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany"],["dc.contributor.affiliation","Roy, Nina; 11German Center for Neurodegenerative Diseases, Bonn, Germany"],["dc.contributor.affiliation","Scheffler, Klaus; 25Department for Biomedical Magnetic Resonance, University of Tübingen, Tübingen, Germany"],["dc.contributor.affiliation","Schneider, Anja; 11German Center for Neurodegenerative Diseases, Bonn, Germany"],["dc.contributor.affiliation","Spottke, Annika; 11German Center for Neurodegenerative Diseases, Bonn, Germany"],["dc.contributor.affiliation","Teipel, Stefan J.; 14German Center for Neurodegenerative Diseases, Rostock, Germany"],["dc.contributor.affiliation","Wiltfang, Jens; 5Department of Psychiatry and Psychotherapy, University Medical Center, University of Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Wolfsgruber, Steffen; 11German Center for Neurodegenerative Diseases, Bonn, Germany"],["dc.contributor.affiliation","Yakupov, Renat; 9German Center for Neurodegenerative Diseases, Magdeburg, Germany"],["dc.contributor.affiliation","Düzel, Emrah; 9German Center for Neurodegenerative Diseases, Magdeburg, Germany"],["dc.contributor.affiliation","Jessen, Frank; 11German Center for Neurodegenerative Diseases, Bonn, Germany"],["dc.contributor.affiliation","Röske, Sandra; 11German Center for Neurodegenerative Diseases, Bonn, Germany"],["dc.contributor.affiliation","Wagner, Michael; 11German Center for Neurodegenerative Diseases, Bonn, Germany"],["dc.contributor.affiliation","Kempermann, Gerd; 1German Center for Neurodegenerative Diseases, Dresden, Germany"],["dc.contributor.affiliation","Wirth, Miranka; 1German Center for Neurodegenerative Diseases, Dresden, Germany"],["dc.contributor.author","Böttcher, Adriana"],["dc.contributor.author","Zarucha, Alexis"],["dc.contributor.author","Köbe, Theresa"],["dc.contributor.author","Gaubert, Malo"],["dc.contributor.author","Höppner, Angela"],["dc.contributor.author","Altenstein, Slawek"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Buerger, Katharina"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Dobisch, Laura"],["dc.contributor.author","Wirth, Miranka"],["dc.contributor.author","Ewers, Michael"],["dc.contributor.author","Fliessbach, Klaus"],["dc.contributor.author","Freiesleben, Silka Dawn"],["dc.contributor.author","Frommann, Ingo"],["dc.contributor.author","Haynes, John Dylan"],["dc.contributor.author","Janowitz, Daniel"],["dc.contributor.author","Kilimann, Ingo"],["dc.contributor.author","Kleineidam, Luca"],["dc.contributor.author","Laske, Christoph"],["dc.contributor.author","Maier, Franziska"],["dc.contributor.author","Metzger, Coraline"],["dc.contributor.author","Munk, Matthias H. J."],["dc.contributor.author","Perneczky, Robert"],["dc.contributor.author","Peters, Oliver"],["dc.contributor.author","Priller, Josef"],["dc.contributor.author","Rauchmann, Boris-Stephan"],["dc.contributor.author","Roy, Nina"],["dc.contributor.author","Scheffler, Klaus"],["dc.contributor.author","Schneider, Anja"],["dc.contributor.author","Spottke, Annika"],["dc.contributor.author","Teipel, Stefan J."],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Wolfsgruber, Steffen"],["dc.contributor.author","Yakupov, Renat"],["dc.contributor.author","Düzel, Emrah"],["dc.contributor.author","Jessen, Frank"],["dc.contributor.author","Röske, Sandra"],["dc.contributor.author","Wagner, Michael"],["dc.contributor.author","Kempermann, Gerd"],["dc.date.accessioned","2022-10-04T10:21:56Z"],["dc.date.available","2022-10-04T10:21:56Z"],["dc.date.issued","2022"],["dc.date.updated","2022-11-11T13:14:36Z"],["dc.description.abstract","Regular musical activity as a complex multimodal lifestyle activity is proposed to be protective against age-related cognitive decline and Alzheimer’s disease. This cross-sectional study investigated the association and interplay between musical instrument playing during life, multi-domain cognitive abilities and brain morphology in older adults (OA) from the DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) study. Participants reporting having played a musical instrument across three life periods (\r\n n\r\n = 70) were compared to controls without a history of musical instrument playing (\r\n n\r\n = 70), well-matched for reserve proxies of education, intelligence, socioeconomic status and physical activity. Participants with musical activity outperformed controls in global cognition, working memory, executive functions, language, and visuospatial abilities, with no effects seen for learning and memory. The musically active group had greater gray matter volume in the somatosensory area, but did not differ from controls in higher-order frontal, temporal, or hippocampal volumes. However, the association between gray matter volume in distributed frontal-to-temporal regions and cognitive abilities was enhanced in participants with musical activity compared to controls. We show that playing a musical instrument during life relates to better late-life cognitive abilities and greater brain capacities in OA. Musical activity may serve as a multimodal enrichment strategy that could help preserve cognitive and brain health in late life. Longitudinal and interventional studies are needed to support this notion."],["dc.identifier.doi","10.3389/fpsyg.2022.945709"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114545"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-600"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1664-1078"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Musical Activity During Life Is Associated With Multi-Domain Cognitive and Brain Benefits in Older Adults"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","682139"],["dc.bibliographiccitation.journal","Frontiers in oral health"],["dc.bibliographiccitation.volume","2"],["dc.contributor.affiliation","Schaper, Sophie; 1Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Meyer-Rötz, Sinja; 1Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Bartels, Claudia; 1Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Wiltfang, Jens; 1Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Rödig, Tina; 4Department of Preventive Dentistry, Periodontology and Cariology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Schott, Björn H.; 1Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Belz, Michael; 1Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.author","Schaper, Sophie"],["dc.contributor.author","Meyer-Rötz, Sinja Henrike"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Rödig, Tina"],["dc.contributor.author","Schott, Björn H."],["dc.contributor.author","Belz, Michael"],["dc.date.accessioned","2022-04-07T10:59:59Z"],["dc.date.available","2022-04-07T10:59:59Z"],["dc.date.issued","2021"],["dc.date.updated","2022-09-06T17:14:38Z"],["dc.description.abstract","For patients with dementia, dental care can pose a considerable challenge due to cognitive impairment, behavioral, and psychological symptoms, and (often subsequently) limited autonomous oral care. In this study, we aimed to assess the proficiency of dentists in general practice in the outpatient dental care of these patients. A total of 119 dentists from private practices in Lower Saxony, Germany, participated in this study. Concerning treatment of patients with dementia, they provided details about (1) practice equipment/consultation, (2) training/expertise, and (3) special circumstances of dental treatment. Participating dentists predominantly reported to use medical aids (e.g., positioning cushions) to improve the treatment situation for patients with dementia. Over two thirds (68.6%) offered consultations in nursing homes, and at the patients' homes (47.0%). The training rate was remarkably low in the field of gerodontology for dentists and their practice staff (<10%), however, 54.5% expressed interest in such training. The majority of dentists reportedly adapted their treatment strategy to the needs of patients with dementia (e.g., communication, inclusion of caregivers, time management). Furthermore, most participants adapted dental treatment adequately (e.g., strict indication for tooth extraction, simple design of dental prostheses). In summary, even though training in the field of gerodontology must be considered insufficient, most dentists in this study showed an adequate adaptation of their treatment strategy as well as consideration of dental characteristics in patients with dementia, along with interest in trainings. We conclude that dementia-specific training should be expanded in the field of dentistry, preferably already at university level."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.3389/froh.2021.682139"],["dc.identifier.pmid","35048026"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/106463"],["dc.language.iso","en"],["dc.relation.eissn","2673-4842"],["dc.relation.issn","2673-4842"],["dc.relation.orgunit","Klinik für Psychiatrie und Psychotherapie"],["dc.relation.orgunit","Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)"],["dc.rights","CC BY 4.0"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Dental Care of Patients With Dementia: A Survey on Practice Equipment, Training, and Dental Treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Aging Neuroscience"],["dc.bibliographiccitation.volume","13"],["dc.contributor.affiliation","Hansen, Niels; 1Department of Psychiatry and Psychotherapy, Göttingen, Germany"],["dc.contributor.affiliation","Singh, Aditya; 1Department of Psychiatry and Psychotherapy, Göttingen, Germany"],["dc.contributor.affiliation","Bartels, Claudia; 1Department of Psychiatry and Psychotherapy, Göttingen, Germany"],["dc.contributor.affiliation","Brosseron, Frederic; 3German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany"],["dc.contributor.affiliation","Buerger, Katharina; 5German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany"],["dc.contributor.affiliation","Cetindag, Arda C.; 7Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany"],["dc.contributor.affiliation","Dobisch, Laura; 9German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany"],["dc.contributor.affiliation","Dechent, Peter; 10MR-Research in Neurology and Psychiatry, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Ertl-Wagner, Birgit B.; 11Institute for Clinical Radiology, Ludwig-Maximilians-University, Munich, Germany"],["dc.contributor.affiliation","Fliessbach, Klaus; 3German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany"],["dc.contributor.affiliation","Haynes, John D.; 12Bernstein Center for Computational Neuroscience, Charité—Universitätsmedizin, Berlin, Germany"],["dc.contributor.affiliation","Heneka, Michael T.; 3German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany"],["dc.contributor.affiliation","Janowitz, Daniel; 6Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany"],["dc.contributor.affiliation","Kilimann, Ingo; 13German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany"],["dc.contributor.affiliation","Laske, Christoph; 15German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany"],["dc.contributor.affiliation","Metzger, Coraline D.; 9German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany"],["dc.contributor.affiliation","Munk, Matthias H.; 15German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany"],["dc.contributor.affiliation","Peters, Oliver; 7Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany"],["dc.contributor.affiliation","Priller, Josef; 8German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany"],["dc.contributor.affiliation","Roy, Nina; 3German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany"],["dc.contributor.affiliation","Scheffler, Klaus; 21Department for Biomedical Magnetic Resonance, University of Tübingen, Tübingen, Germany"],["dc.contributor.affiliation","Schneider, Anja; 3German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany"],["dc.contributor.affiliation","Spottke, Annika; 3German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany"],["dc.contributor.affiliation","Spruth, Eike J.; 8German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany"],["dc.contributor.affiliation","Teipel, Stefan; 13German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany"],["dc.contributor.affiliation","Tscheuschler, Maike; 23Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, Cologne, Germany"],["dc.contributor.affiliation","Vukovich, Ruth; 1Department of Psychiatry and Psychotherapy, Göttingen, Germany"],["dc.contributor.affiliation","Wiltfang, Jens; 1Department of Psychiatry and Psychotherapy, Göttingen, Germany"],["dc.contributor.affiliation","Duezel, Emrah; 9German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany"],["dc.contributor.affiliation","Jessen, Frank; 23Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, Cologne, Germany"],["dc.contributor.affiliation","Goya-Maldonado, Roberto; 1Department of Psychiatry and Psychotherapy, Göttingen, Germany"],["dc.contributor.author","Hansen, Niels"],["dc.contributor.author","Singh, Aditya"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Brosseron, Frederic"],["dc.contributor.author","Buerger, Katharina"],["dc.contributor.author","Cetindag, Arda C."],["dc.contributor.author","Dobisch, Laura"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Ertl-Wagner, Birgit B."],["dc.contributor.author","Goya-Maldonado, Roberto"],["dc.contributor.author","Fliessbach, Klaus"],["dc.contributor.author","Haynes, John D."],["dc.contributor.author","Heneka, Michael T."],["dc.contributor.author","Janowitz, Daniel"],["dc.contributor.author","Kilimann, Ingo"],["dc.contributor.author","Laske, Christoph"],["dc.contributor.author","Metzger, Coraline D."],["dc.contributor.author","Munk, Matthias H."],["dc.contributor.author","Peters, Oliver"],["dc.contributor.author","Priller, Josef"],["dc.contributor.author","Roy, Nina"],["dc.contributor.author","Scheffler, Klaus"],["dc.contributor.author","Schneider, Anja"],["dc.contributor.author","Spottke, Annika"],["dc.contributor.author","Spruth, Eike J."],["dc.contributor.author","Teipel, Stefan"],["dc.contributor.author","Tscheuschler, Maike"],["dc.contributor.author","Vukovich, Ruth"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Duezel, Emrah"],["dc.contributor.author","Jessen, Frank"],["dc.date.accessioned","2021-06-01T09:42:25Z"],["dc.date.available","2021-06-01T09:42:25Z"],["dc.date.issued","2021"],["dc.date.updated","2022-02-09T13:21:10Z"],["dc.description.abstract","Background: The hippocampus and its subfields (HippSub) are reported to be diminished in patients with Alzheimer's disease (AD), bipolar disorder (BD), and major depressive disorder (MDD). We examined these groups vs healthy controls (HC) to reveal HippSub alterations between diseases. Methods: We segmented 3T-MRI T2-weighted hippocampal images of 67 HC, 58 BD, and MDD patients from the AFFDIS study and 137 patients from the DELCODE study assessing cognitive decline, including subjective cognitive decline (SCD), amnestic mild cognitive impairment (aMCI), and AD, via Free Surfer 6.0 to compare volumes across groups. Results: Groups differed significantly in several HippSub volumes, particularly between patients with AD and mood disorders. In comparison to HC, significant lower volumes appear in aMCI and AD groups in specific subfields. Smaller volumes in the left presubiculum are detected in aMCI and AD patients, differing from the BD group. A significant linear regression is seen between left hippocampus volume and duration since the first depressive episode. Conclusions: HippSub volume alterations were observed in AD, but not in early-onset MDD and BD, reinforcing the notion of different neural mechanisms in hippocampal degeneration. Moreover, duration since the first depressive episode was a relevant factor explaining the lower left hippocampal volumes present in groups."],["dc.identifier.doi","10.3389/fnagi.2021.626974"],["dc.identifier.eissn","1663-4365"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85247"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1663-4365"],["dc.rights","http://creativecommons.org/licenses/by/4.0/"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Psychiatry"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Hansen, Niels"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Stöcker, Winfried"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Timäus, Charles"],["dc.date.accessioned","2021-08-12T07:45:48Z"],["dc.date.available","2021-08-12T07:45:48Z"],["dc.date.issued","2021"],["dc.description.abstract","Flotillin proteins are involved in neurodegeneration and T-cell immunity. Here, we report the case of 65-year-old woman who presented with dementia, depressive symptoms, and a patient history involving speech problems. As diagnostics methods we applied magnetic resonance imaging, clinical examination, extensive neuropsychological testing, and cerebrospinal fluid analysis. Neuropsychological testing revealed major cognitive decline in attentional, executive, and memory functions together with impaired activities of daily living. The cerebrospinal fluid showed elevated phosphorylated tau protein 181. We identified serum autoantibodies against the flotillin 1/2 complex. Immunotherapy entailing four cycles of high-dose steroids resulted in less cognitive dysfunction along with reduced depressive symptoms in the second follow-up after starting steroids. In conclusion: probable autoimmune-mediated dementia associated with anti-flotillin 1/2 complex autoantibodies expands the phenotypic spectrum of anti-flotillin 1/2 antibody disease."],["dc.description.abstract","Flotillin proteins are involved in neurodegeneration and T-cell immunity. Here, we report the case of 65-year-old woman who presented with dementia, depressive symptoms, and a patient history involving speech problems. As diagnostics methods we applied magnetic resonance imaging, clinical examination, extensive neuropsychological testing, and cerebrospinal fluid analysis. Neuropsychological testing revealed major cognitive decline in attentional, executive, and memory functions together with impaired activities of daily living. The cerebrospinal fluid showed elevated phosphorylated tau protein 181. We identified serum autoantibodies against the flotillin 1/2 complex. Immunotherapy entailing four cycles of high-dose steroids resulted in less cognitive dysfunction along with reduced depressive symptoms in the second follow-up after starting steroids. In conclusion: probable autoimmune-mediated dementia associated with anti-flotillin 1/2 complex autoantibodies expands the phenotypic spectrum of anti-flotillin 1/2 antibody disease."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.3389/fpsyt.2021.626121"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88553"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.relation.eissn","1664-0640"],["dc.rights","CC BY 4.0"],["dc.title","Case Report: Anti-flotillin 1/2 Autoantibody-Associated Atypical Dementia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Neurology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.affiliation","Hansen, Niels; 1Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Göttingen, Germany"],["dc.contributor.affiliation","Malchow, Berend; 1Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Göttingen, Germany"],["dc.contributor.affiliation","Teegen, Bianca; 2Euroimmun Laboratory, Lübeck, Germany"],["dc.contributor.affiliation","Wiltfang, Jens; 1Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Göttingen, Germany"],["dc.contributor.affiliation","Bartels, Claudia; 1Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Göttingen, Germany"],["dc.contributor.author","Hansen, Niels"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Teegen, Bianca"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Bartels, Claudia"],["dc.date.accessioned","2022-06-30T09:44:18Z"],["dc.date.available","2022-06-30T09:44:18Z"],["dc.date.issued","2022-06-16"],["dc.date.updated","2022-06-30T09:37:56Z"],["dc.description.abstract","Background Neurochondrin autoimmunity is a rare disorder mainly associated with cerebellar and vestibular syndromes. Our report aims to enlarge its phenotypic spectrum to encompass major cognitive disorder with very late onset never before reported in conjunction with neurochondrin antibodies. Methods We describe the case of an 85-year-old woman who presented in our memory clinic. Retrospective analysis of patient records included cerebrospinal fluid (CSF) analysis, magnetic resonance imaging (MRI), and neuropsychological testing using the CERAD-plus. Results Because of her unknown onset of progressive cognitive dysfunction in conjunction with speech and language problems, we decided to take an extensive differential diagnostic approach including a search for neural autoantibodies potentially involved in cognitive impairment. Our patient presented serum and CSF neurochondrin autoantibodies. Further CSF analysis revealed elevated tau and ptau 181 protein as well as a reduced Aß42/40 ratio in CSF, thus matching a biomarker profile of Alzheimer's disease (AD). Neuropsychological tests revealed predominant and severe deficits in verbal and visual memory. Her MRI showed reduced parietal and cerebellar brain volume. Discussion Taken together, this case reveals the novelty of a patient with a CSF-based and typical clinical and imaging profile of AD. She is also likely to have neurochondrin autoimmunity, as we detected neurochondrin autoantibodies in her CSF; we therefore diagnosed AD dementia associated with neurochondrin antibodies. Our case expands the spectrum of neurochondrin autoimmunity to disorders involving major cognitive disorder such as AD dementia. Furthermore, we speculate that neurochondrin autoimmunity might have triggered an acceleration of AD symptoms as its onset was reported only after a short 6-month interval via a synergistic or negatively additive hybrid mechanism of action between neurodegeneration and autoimmunity."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3389/fneur.2022.879009"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/111910"],["dc.language.iso","en"],["dc.relation.eissn","1664-2295"],["dc.rights","CC BY 4.0"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Case Report: Alzheimer's Dementia Associated With Cerebrospinal Fluid Neurochondrin Autoantibodies"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","455"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Alzheimer's Disease"],["dc.bibliographiccitation.lastpage","465"],["dc.bibliographiccitation.volume","72"],["dc.contributor.author","Teipel, Stefan J."],["dc.contributor.author","Kuper-Smith, Jan O."],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Brosseron, Frederic"],["dc.contributor.author","Buchmann, Martina"],["dc.contributor.author","Buerger, Katharina"],["dc.contributor.author","Catak, Cihan"],["dc.contributor.author","Janowitz, Daniel"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Dobisch, Laura"],["dc.contributor.author","Ertl-Wagner, Birgit"],["dc.contributor.author","Fließbach, Klaus"],["dc.contributor.author","Haynes, John-Dylan"],["dc.contributor.author","Heneka, Michael T."],["dc.contributor.author","Kilimann, Ingo"],["dc.contributor.author","Laske, Christoph"],["dc.contributor.author","Li, Siyao"],["dc.contributor.author","Menne, Felix"],["dc.contributor.author","Metzger, Coraline D."],["dc.contributor.author","Priller, Josef"],["dc.contributor.author","Pross, Verena"],["dc.contributor.author","Ramirez, Alfredo"],["dc.contributor.author","Scheffler, Klaus"],["dc.contributor.author","Schneider, Anja"],["dc.contributor.author","Spottke, Annika"],["dc.contributor.author","Spruth, Eike J."],["dc.contributor.author","Wagner, Michael"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Wolfsgruber, Steffen"],["dc.contributor.author","Düzel, Emrah"],["dc.contributor.author","Jessen, Frank"],["dc.contributor.author","Dyrba, Martin"],["dc.contributor.editor","Zhou, Juan Helen"],["dc.date.accessioned","2020-12-10T18:44:13Z"],["dc.date.available","2020-12-10T18:44:13Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.3233/JAD-190446"],["dc.identifier.eissn","1875-8908"],["dc.identifier.issn","1387-2877"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16953"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78366"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimer’s Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","760021"],["dc.bibliographiccitation.journal","Frontiers in Immunology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.affiliation","Hansen, Niels; \r\n1\r\nDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Stöcker, Winfried; \r\n2\r\nEuroimmun Reference Laboratory, Luebeck, Germany"],["dc.contributor.affiliation","Wiltfang, Jens; \r\n1\r\nDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Bartels, Claudia; \r\n1\r\nDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Rentzsch, Kristin; \r\n2\r\nEuroimmun Reference Laboratory, Luebeck, Germany"],["dc.contributor.affiliation","Bouter, Caroline; \r\n5\r\nDepartment of Nuclear Medicine, University Medical Center Göttingen, Goettingen, Germany"],["dc.contributor.author","Hansen, Niels"],["dc.contributor.author","Stöcker, Winfried"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Rentzsch, Kristin"],["dc.contributor.author","Bouter, Caroline"],["dc.date.accessioned","2022-02-01T10:31:39Z"],["dc.date.available","2022-02-01T10:31:39Z"],["dc.date.issued","2022"],["dc.date.updated","2022-02-09T13:19:47Z"],["dc.description.abstract","Background Frontotemporal lobar degeneration is a heterogeneous disorder entailing a semantic variant of primary progressive aphasia (svPPA). A subtype of frontotemporal dementia associated with glutamate receptor subunit 3 (GluA3) antibody of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) was recently identified. Here, we describe the novelty of a svPPA associated with anti-glial fibrillary acid protein (GFAP) antibodies. Methods To diagnose this 68-year-old woman we conducted a clinical examination, neuropsychological testing, CSF analysis, MRI and 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET)/computed tomography (CT) imaging. Results The clinical phenotype corresponds to a svPPA based on impaired confrontation naming and single-word comprehension. In addition, we observed spared speech production, impaired object knowledge, and surface dyslexia - further supporting the diagnosis of svPPA. Additional characteristic imaging features such as anterior temporal hypometabolism in 18F-FDG PET/CT confirmed patient’s svPPA diagnosis. CSF analysis revealed signs of axonal degeneration, as both tau and phosphorylated tau proteins exceeded normal levels. Her serum showed anti-GFAP autoantibodies. Conclusion We diagnosed a svPPA in this patient and report an association between serum anti-GFAP antibodies and svPPA never reported in the literature so far, thereby expanding the clinical spectrum of svPPA and anti-GFAP-antibody related disease. Further research is needed to elucidate the underlying immunopathology of this disease entity to ultimately improve treatment."],["dc.description.sponsorship","Georg-August-Universität Göttingen"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.3389/fimmu.2021.760021"],["dc.identifier.eissn","1664-3224"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/98914"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-517"],["dc.relation.eissn","1664-3224"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Case Report: Semantic Variant of Primary Progressive Aphasia Associated With Anti-Glial Fibrillary Acid Protein Autoantibodies"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Alzheimer's Research & Therapy"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Sannemann, Lena"],["dc.contributor.author","Schild, Ann-Katrin"],["dc.contributor.author","Altenstein, Slawek"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Brosseron, Frederic"],["dc.contributor.author","Buerger, Katharina"],["dc.contributor.author","Cosma, Nicoleta Carmen"],["dc.contributor.author","Fliessbach, Klaus"],["dc.contributor.author","Freiesleben, Silka Dawn"],["dc.contributor.author","Glanz, Wenzel"],["dc.contributor.author","Heneka, Michael T."],["dc.contributor.author","Janowitz, Daniel"],["dc.contributor.author","Kilimann, Ingo"],["dc.contributor.author","Kobeleva, Xenia"],["dc.contributor.author","Laske, Christoph"],["dc.contributor.author","Metzger, Coraline D."],["dc.contributor.author","Munk, Matthias H. J."],["dc.contributor.author","Perneczky, Robert"],["dc.contributor.author","Peters, Oliver"],["dc.contributor.author","Polcher, Alexandra"],["dc.contributor.author","Priller, Josef"],["dc.contributor.author","Rauchmann, Boris"],["dc.contributor.author","Rösch, Christina"],["dc.contributor.author","Rudolph, Janna"],["dc.contributor.author","Schneider, Anja"],["dc.contributor.author","Spottke, Annika"],["dc.contributor.author","Spruth, Eike Jakob"],["dc.contributor.author","Teipel, Stefan"],["dc.contributor.author","Vukovich, Ruth"],["dc.contributor.author","Wagner, Michael"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Wolfsgruber, Steffen"],["dc.contributor.author","Duezel, Emrah"],["dc.contributor.author","Jessen, Frank"],["dc.date.accessioned","2021-04-14T08:31:19Z"],["dc.date.available","2021-04-14T08:31:19Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1186/s13195-020-00701-7"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17604"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83557"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1758-9193"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]